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The concept of a cancer stem cell is not a new one, being first suggested over 100 years ago. Over recent years the concept has
enjoyed renewed enthusiasm, partly because of our growing understanding of the nature of somatic stem cells, but also because of a
growing realisation that the development of strategies that target cancer stem cells may offer considerable advantages over
conventional approaches. However, despite this renewed enthusiasm the existence of cancer stem cells remains controversial in
many tumour types and any potential relationship to the normal stem cell pool remains poorly defined. This review summarises key
elements of our understanding of the normal stem cell populations within animal models of the predominant cancer prone epithelial
tissues, and further investigates the potential links between these populations and putative cancer stem cells.
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CANCER PRONE TISSUES
Of approximately 200 different types of cancer, four account for
over half of all the new cases diagnosed in Britain every year –
breast, lung, colorectal and prostate (Toms, 2004). There is also a
fifth type of, cancer which evades the national statistics database as
it is regularly diagnosed and successfully treated within GP
surgeries – non-melanoma skin cancer (NMSC) (Toms, 2004). It is
estimated that at least 100000 cases of NMSC are diagnosed each
year in the United Kingdom, which is higher than the sum total of
breast and lung cases combined (Toms, 2004). This figure is on the
increase and consequently the skin can also be considered as a
cancer prone organ.
The lung represents a rather special case for inclusion as a
cancer prone tissue. In the early 1900s lung cancer was a rare
disease in the UK, but rates increased to a peak in the late 1970s
when smoking was at its most popular. As the number of people
smoking is slowly decreasing, so the cases of lung cancer are also
beginning to decrease. In fact, the lungs have a remarkable
capacity to regenerate and repair damaged tissue. This suggests
that, aside from tobacco exposure, the lungs are actually
comparatively cancer resistant. However, while smoking persists
as a global habit the frequency of lung cancer will remain high and
therefore knowledge regarding lung stem cells is of potential value
for the development of future therapies.
STEM CELLS WITHIN EPITHELIAL TISSUES
Epithelial layers are composed of a sheet of cells (or multiple
sheets), which constitute the linings and surfaces of the body.
The epithelium provides a physical barrier from the external
environment, facilitating the absorption of water and nutrients,
and regulating glandular secretions. Epithelial layers are thought
to be maintained by a small population of tissue-specific adult
somatic stem cells, which have the potential to produce all the
different cell types present in the tissue they reside in. Even organs
which were considered to consist entirely of terminally differen-
tiated cells, such as the brain, have been shown to contain small
populations of pluripotent cells with a high capacity to divide and
differentiate into the major cell types of the nervous system
(Reynolds and Weiss, 1996).
The current model of adult epithelial somatic stem cells has
been obtained from work performed primarily in organs, which
have a high proliferative capacity such as the intestine, skin and
mammary gland. Adult epithelial somatic stem cells are found in
very low numbers and are protected in well vascularised niches
which provide essential cues to strictly regulate their function
(Scadden, 2006). Stem cells are characterised by two functions
(reviewed in Reya et al, 2001). First, they are able to self-renew.
Second, through asymmetric division, they are able to produce
progenitor cells which initially bear very similar characteristics to
the stem cell, but become less able to self-renew with each
subsequent division, and eventually stop dividing and terminally
differentiate into a mature tissue-specific cell type. Through this
mechanism stem cells are able to produce all the multiple cell types
found in the tissue from which they reside. The daughter cells also
have a high proliferation rate and are often termed transit-
amplifying cells. It is the transit-amplifying cells that provide the
number of cells required for homoeostasis of the tissue in which
they reside, as endogenous somatic stem cells are normally
considered to have a low frequency of division (replicative
quiescence).
PROSTATE
Although the prostate is a relatively quiescent organ with regards
to proliferation, it has considerable regenerative capacity. For
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can be completely rescued if androgen is resupplied – a cycle that
can be repeated up to 30 times in the same animal (Isaacs, 1985).
Several molecular markers of the prostatic stem cell have
recently been proposed, including a2b1 integrin in conjunction
with CD133 (Richardson et al, 2004; Tsujimura et al, 2007) and
Sca-1 (Xin et al, 2005). Human a2b1
hi/CD133
þ-enriched cells were
able to establish and maintain a prostate epithelium when
transplanted in to an immunodeficient mouse, although an entire,
functional prostate organ did not develop (Richardson et al, 2004).
The mouse homologue of CD133, prominin, also enriched for cells
which displayed stem cell properties in vitro, and is expressed in
the basal layer of the proximal region of the mouse prostate
(Tsujimura et al, 2007). Similar results were observed in mice
using Sca-1 enriched cells, which were able to display stem cell
qualities in vivo and initiate tumourigenesis in conjunction with
activated AKT (Xin et al, 2005).
Recently, Lawson et al (2007) demonstrated that a CD45
 /
CD31
 /Ter119
 /Sca-1
þ/CD49f
þ cell subpopulation isolated from
mouse prostate is enriched for cells capable of both colony and
sphere formation in vitro. These cells can also differentiate to
produce prostatic tubule structures in vivo, containing both basal
and luminal cells, when injected subcutaneously into SCID mice.
However, only 1 in 35 enriched cells was capable of developing
prostate structures in vivo, suggesting that the stem cell is not
defined by these markers and that further markers are also
required to be expressed correctly (positively or negatively)
(Lawson et al, 2007). CD45
  CD31
  Ter119
  Sca-1
þ CD49f
þ
enriched cells localised to the basal layer within the proximal
region of the prostate after injection suggesting that this is the
endogenous location of stem cells in the murine prostate (Figure 1).
To date, none of the enriched cells used for in vivo assays has
developed into an entire functional prostate, demonstrating that
although these enriched cells have stem-like qualities they do not
possess all the unique properties required for total organ
regeneration.
The markers used to enrich for potential prostate stem cells have
also been used to enrich cells which have stem cell properties in
other epithelial tissues, including brain (CD133 (Singh et al,
2003)), mammary gland (CD133 (Tsujimura et al, 2007)); CD49f
(Stingl et al, 2006) and lung (Sca1, (Kim et al, 2005)), suggesting
significant common features between stem cells of different tissues.
MAMMARY
The Mammary gland is composed of a branching network of ducts
that terminate in sac-like lobules (Figure 1). The massive
expansion of epithelium during puberty and pregnancy, together
with the remarkable regenerative capacity of successive reproduc-
tive cycles, suggests that the mammary epithelium contains a
population of somatic stem cells.
Cell surface markers (CD24
med CD49f
hi) have been used to
isolate cell populations from adult murine mammary gland
enriched for the capacity to initiate new mammary outgrowths
when transplanted into the epithelial-free fat pads (Stingl et al,
2006). The existence of a mammary stem cell has now clearly been
demonstrated using cell surface markers (Lin
  CD29
hi CD24
þ)t o
enrich for a single basal/myoepithelial cell from the murine
mammary gland that was able to reconstitute an entire functional
gland using the same assay (Shackleton et al, 2006). These cells are
slow-cycling and express a number of genes that have been
implicated as stem cell markers in other tissues such as Sca-1 in
the prostate (Xin et al, 2005) and keratin 14 in the skin (Morris
et al, 2004). However, not all Lin
  (CD45, Ter119 and CD31
collectively called Lin) CD29
hi CD24
þ cells were capable of
reconstituting a functional mammary gland – only six out of 102
implanted single cells. Thus, the exact nature of the stem cell is
unknown, and further markers, in addition to Lin
  CD29
hi
CD24
þ, are also required to genuinely define the stem cell
population.
The precise location of the mammary stem cell remains
uncertain, but molecular features such as keratin 14 indicate a
basal position in the mammary epithelium of the adult gland
(Stingl et al, 2006) (Figure 1).
SKIN
The skin epidermis is a stratified (layered) squamous epithelium
containing hair follicles and sebaceous glands (Figure 1). The
interfollicular epidermis (IFE) is composed of a basal layer of
proliferative cells, which then differentiate into the distinct
suprabasal layers above. The suprabasal layers are continually
replaced by cells from the basal layer as the stratum corneum is
sloughed off. This constant regeneration is strongly suggestive of a
resident population of stem cells in the basal layer of the skin
(Blanpain et al, 2004).
The adult hair follicle undergoes a periodic cycle of growth,
destruction and rest which requires a population of stem cells that
reside in a region called the bulge, located under the sebaceous
gland (Figure 1) (Blanpain et al, 2004). Transplantation of a
dissected bulge region into an immunodeficient (NOD/SCID)
mouse demonstrated that transplanted cells were able to
differentiate into all the epithelial cell types of the skin (Oshima
et al, 2001). Subsequent to this experiment, CD34
þ a6 integrin
þ
enrichment was used to isolate a single cell from the bulge region.
Transplantation of these cells into a nude mouse resulted in tufts
of hair at the graft site, and lineage tracing revealed contribution of
the grafted cell to the epidermis, sebaceous glands and hair follicle
(Blanpain et al, 2004). These results demonstrated the multi-
potency of CD34
þ a6 integrin
þ-enriched cells from the bulge and
consequently their definition as genuine stem cells.
Lineage tracing experiments in mice using a non-invasive
transgenic approach have indicated that a stem cell population also
exists in the IFE to facilitate the continuous renewal of the skin
(Ro and Rannala, 2004). However, interfollicular stem cells have
yet to be isolated, and there are no reliable markers of this
population at present. There is also evidence from lineage tracing
of IFE progenitors to suggest that IFE homoeostasis occurs
independently from stem cells, instead utilising a single population
of persistent progenitors (Clayton et al, 2007). This has also been
observed during repair of the pancreas after injury (Dor et al,
2004) and challenges the ‘stem cell/transit-amplifying cells’ model
by suggesting that progenitor cells are not always transient, and
that differentiated cells can divide to maintain homoeostasis of
adult tissues.
INTESTINE
The mammalian intestinal epithelium consists of a single layer of
epithelial cells, which are organised into finger-like projections
(villi) that extend into the lumen of the gut and pocket shaped
crypts at the base (Figure 1). BrdU label-retaining assays suggest
that the stem cells reside in the crypt (Potten et al, 2002), but
unlike the work performed on the cornea (Cotsarelis et al, 1989)
and hair follicle (Cotsarelis et al, 1990), no functional assay has yet
been performed to confirm this.
Each adult crypt is monoclonal, but the villi are polyclonal and
contain cells from several crypt. Therefore each crypt contains
a single active stem cell (Figure 1). However, actions that are
deleterious to the endogenous stem cell, such as exogenous DNA
damage or the removal of crucial transcription factors such as
C-Myc (Muncan et al, 2006), triggers the death of the stem cell and
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stem cell.
The characterisation of intestinal stem cells has proved
challenging, and presently there is no direct functional assay.
Several molecules have been proposed to mark the intestinal stem
cell population, such as Musashi and phospho-Pten (He et al,
2007). However, these remain unproven as definitive markers of
the intestinal stem cell. Recently, there has been a significant
advance from Hans Clevers’ laboratory, based on a screen of Wnt
target genes (Barker et al, 2007). Wnt signalling is critical for both
the development of the intestine and the homoeostasis of the adult
tissue (Clarke, 2006). Deregulation of the Wnt pathway by removal
of Apc from the adult murine intestine immediately imposes a
phenotype mimicking tumourigenesis (Sansom et al, 2004), a
phenotype entirely dependent on the Wnt target C-Myc (Sansom
et al, 2007). Based on array data, it was speculated that the
intestinal stem cell will express some Wnt target genes. One of
these Wnt targets, Lgr5, a G-protein-coupled receptor gene, was
found to be expressed in slender cells between the Paneth cells at
the base of the crypt (Barker et al, 2007). Previously, long-term
label-retaining experiments had suggested the putative stem cell
was located just above the Paneth cells at position 4-6 (Potten et al,
1997). Lineage tracing using a Cre inducible Lac-Z has now shown
that Lgr5
þ cells give rise to all intestinal epithelial cells over a
60-day period, strongly suggesting that Lgr5
þ cells are either
synonymous with the intestinal stem cell, or that they are markedly
enriched for the intestinal stem cell (Barker et al, 2007).
Unlike stem cells discovered in other organs such as the skin
and mammary gland, the Lgr5
þ intestinal stem cells do not have a
slow rate of division. Conversely, they appear to divide frequently,
a condition which may reflect the fact that the intestine is the most
rapidly self-renewing tissue in adult mammals (Barker et al, 2007).
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Figure 1 Location of stem cells. Prostate gland. The putative prostatic stem cells are located in the basal cells surrounding the columnar secretory cells of
the distal prostatic duct. Hair-follicle. Skin stem cells are located under the sebaceous gland in a region known as the bulge. During rest periods, stem cells of
the bulge region form the base of the hair-follicle. During the start of each new growth cycle stem cells located at the base of the bulge become active to
form the highly proliferative new hair germ. The interfollicular epidermis is a stratified epithelium, containing unipotent progenitor cells and transit-amplifying
cells located in the basal layer. Basal cells differentiate upward to form the spinous, granular, and stratum corneum layers of the epidermis. Mammary gland.
The mammary gland consists of a branching network of ducts, terminating in alveolar buds. Mammary stem cells are thought to be located in the basal,
myoepithelial layer, which tightly surrounds the ductal epithelial layer. The secretory alveolar cells are also surrounded by a looser association of
myoepithelial cells. Intestinal crypt. The crypt stem cell had previously been located to position 4–6, just above the base of the crypt. Recent data now
suggests the putative stem cells of the intestine (red) are narrow cells located between Paneth cells near the base of the crypt. Cells leaving the proliferation
zone migrate upward towards the villus tip and differentiate into one of three cell types, enteroendocrine cells, goblet cells, and enterocytes, to form the
villus. A fourth cell type, the Paneth cells, migrate downward to the crypt base. Lungs. The putative lung stem cells are located at the junction between the
branching, bronchial region and the alveolar sac, and express markers from ATII cells and Clara cells.
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reliable marker of the stem cell population in all tissues.
Despite these very clear observations, some debate still remains
over the precise nature of the intestinal stem cell. Most notably,
very similar approaches to those described above have been used
by Sangiorgi and Capecchi (2008) to show that Bmi-1 expression
marks the stem cell, and indeed deletion of Bmi-1-expressing cells
results in crypt ablation. However, the reported positioning of
Bmi-1 positive cells does not precisely overlap with Lgr5 positivity,
suggesting that actually there may be two pools of molecularly
identifiable populations of stem cells within the intestine.
LUNG
The ability of the lungs to repair and regenerate prior to smoke
damage suggests there is a pool of lung stem cells. However, the
pulmonary system has proven a particularly challenging environ-
ment to study stem cells due to its complex structure,
which contains multiple, distinct epithelial regions including
pseudostratified epithelium, columnar epithelium and alveolar
epithelium.
The bronchial epithelial regions are composed mostly of Clara
cells, while the alveolar epithelium consists of type I and type II
(AT2) cells (Figure 1). Clara cells and AT2 cells have both been
implicated as the cells of origin in adenocarcinomas (Neuringer
and Randell, 2004). However, work from Tyler Jacks’ lab on mice
has identified a small population of cells that express both AT2-
specific markers and Clara cell markers (Kim et al, 2005). These
cells, termed BASCs (bronchioalveolar stem cells), were found in
mutant K-ras induced adenocarcinomas and at the bronchioalveo-
lar duct junction of normal lung tissue. In vivo they proliferated in
response to epithelial damage, and exhibited stem cell character-
istics such as self renewal and multipotency when isolated and
cultured. Enrichment of BASCs in K-ras induced tumorigenesis
resulted in an increase in tumour number and size suggesting that
transformed BASCs also play a role during tumorigenesis in the
lung (Kim et al, 2005), although this is yet to be confirmed in an in
vivo assay.
Molecular analysis of BASCs revealed that they were Sca1
þ
CD45
  Pecam
  CD34
þ (Kim et al, 2005). These molecules are also
markers of proposed stem cells from other epithelial tissues
including prostate (Sca1
þ; Xin et al, 2005) and CD45
 ; Lawson
et al, 2007) and skin (CD34
þ; Blanpain et al, 2004), again
suggesting considerable overlap between stem cells from different
organs.
CANCER STEM CELLS
Not all the cells within a tumour are able to proliferate when
isolated from the tumour and grown in culture or transplanted
into a new host. In fact only a very small percentage of cells within
a tumour have the potential to reconstitute a new tumour upon
transplantation (one in every 5.7 10
4 for colon tumours; O’Brien
et al, 2007). This suggests there is a small subpopulation of highly
prolific cells that have tumorigenic potential. The first evidence for
such a population derives from studies by Bonnet and Dick
(Bonnet and Dick, 1997). They demonstrated that only a
subpopulation of CD34
þCD38
  cells, purified from patients with
acute myeloid leukaemia, were able to transfer the disease to
immunodeficient (NOD/SCID) mice.
Since then, cancer stem cells have also been identified through
similar experiments using cell surface markers such as CD133.
Given that stem cells share some common properties, it is perhaps
not surprising that cancer stem cells from different tissues have
some common markers. For example, CD133
þ cells have been
used to enrich for cancer stem cells in both the brain (Singh et al,
2004) and colon (O’Brien et al, 2007; Ricci-Vitiani et al, 2007), and
skin and mammary stem cells both express high levels of
b1-integrin and a6-integrin (Shackleton et al, 2006).
These experiments strongly support the widespread existence of
cancer stem cells; however, the concept still remains controversial
for many tumour types. This has been most clearly argued by
Strasser and co-workers (e.g., Kelly et al, 2007), who have shown
that a variety of leukaemias and lymphomas can be maintained by
syngeneic transfer of dominant populations, rather than minority
‘cancer stem cell’ populations. They suggest that the observation of
minority ‘cancer stem cells’ is often a reflection of the experimental
system used, for example the use of xenotransplantation assays
into a foreign microenvironment.
In summary, the evidence in favour of cancer stem cells
remains strong, but significant issues and doubts remain,
which predominantly arise from uncertainties about the assays
in use. At this point it seems reasonable to conclude that minority
‘stem cell’ populations do exist within some cancers; however, the
broad applicability of this concept to all tumours remains
unproven.
FUNCTIONAL ASSAYS FOR STEM CELLS AND
CANCER STEM CELLS
A functional assay for somatic ‘stemness’ is the ability of a single
isolated cell from an adult organ to generate an entire organ when
transplanted. Thus far, this has only been successfully achieved for
the skin and mammary gland. Although this is the ultimate
experiment to test for stem cell activity, it is also very difficult
to achieve with stem cells from epithelial origins. Epithelial layers
are in contact with many other cell types and tissues such
as fibroblasts, extra cellular matrix and mesenchyme, which
constantly cue and interact with the epithelium. These signals,
such as Wnt and Notch, are critical for the survival and function of
somatic stem cells and pose the challenge of delivering a proposed
somatic stem cell directly into its tissue niche.
Although there are many examples of somatic stem cells, which
can display the characteristics of stem cells in vitro (Table 1), the
next step in defining them as a true stem cell is to develop
functional in vivo assays for these isolated cells. For example, only
one in every 262 CD133
þ cells was able to initiate colon cancer
(O’Brien et al, 2007), demonstrating that although CD133 is a
marker for potential cancer stem cells it is not a definitive marker
for this tissue. A similar situation pertains to the proposed prostate
stem cell marker Sca-1. Sca-1
þ cells can produce prostatic tubules
when transplanted under the kidney capsule of immunodeficient
mice, however, although the structures are smaller, Sca1
  cells
possess the same ability (Xin et al, 2005). Recently CD34 has been
used to enrich a population of cells from a mouse skin tumour
which are able to generate secondary and tertiary tumours upon
transplantation (Malanchi, 2008). Although CD34-positive cells are
potent tumour-initiating cells in comparison to unsorted tumour
cells, the frequency of tumour initiation decreases when the
number of CD34þ cells is reduced. Thus, CD34 expression alone
is not sufficient to mark a skin cancer stem cell but in addition
genes, which currently remain unknown are also required to be
correctly expressed. Therefore, although markers are currently
being identified that often enrich for stem cells and cancer stem
cell populations, these markers are, as yet, often not definitive.
CANCER STEM CELLS AND NORMAL STEM CELLS
The central question of this review is whether the two populations
of normal and neoplastic stem cells are related. It has been self-
evident for many years that there are strong parallels between
‘stemness’ and neoplasia. This is particularly clear from the
development of multipotent embryonal carcinoma cells and
subsequently genuine pluripotent embryonic stem cells, the latter
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that normal stem cells and cancer stem cells share some common
characteristics. These include the signalling pathways that have
been implicated in the normal regulation of somatic stem cells,
such as the Wnt pathway, which are often deregulated during
tumorigenesis.
It is also evident that somatic stem cells possess properties that
may render them more prone to transformation. For example, as
stem cells usually remain in a given tissue for much longer than
their differentiated progeny, the lifetime opportunity to acquire
transforming mutations may be increased. In the intestine,
differentiated cells are sloughed into the intestinal lumen over
the course of four–five days, giving a very short window for a
transformed phenotype to manifest. By contrast, intestinal stem
cells persist in the epithelium to replace the transit-amplifying cells
that are lost, and so offer a semi-permanent target population for
transformation.
The capacity for self renewal may be considered a similar pro-
neoplastic factor. The increasing cell mass of a tumour must
contain cells with the ability to self-renew. As stem cells inherently
possess this mechanism, the path to a functional cancer stem cell
may therefore be considerably shorter than that for a differentiated
somatic cell, which may have to acquire specific mutations to
achieve the same self-renewing properties.
In terms of the cancer stem cell examples given above, examples
of overlap between the normal and cancer stem cell populations
are already beginning to emerge. For example, although little is
known regarding its function, CD133
þ cells isolated from either
normal prostate tissue (Richardson et al, 2004) or brain tumours
(Singh et al, 2003) continued to display somatic stem cell
properties in vitro.
The skin stem cell marker CD34 (along with a6 integrin
þ)i s
also expressed in skin tumours, and has recently been used to
enrich a population of skin tumour cells with potent tumour
initiation properties (Malanchi, 2008 no. 163). This common
marker suggests that skin stem cells are potential targets for
transformation into cancer stem cells; however, the regulation of
the skin stem cells and skin cancer stem cells appears to differ.
Depletion of b-catenin from skin tumours resulted in the loss of
CD34 expression and total regression of the tumour suggesting
that skin cancer stem cells require Wnt signalling. This is
supported by experiments in which c-Myc (a Wnt target) deficient
epidermis is resistant to Ras-induced tumorigenesis through
repression of p21
Cip1 (Oskarsson, 2006 no. 162). However, c-Myc
is surprisingly dispensable for skin homoeostasis indicating that it
may be an attractive target for therapeutic intervention, which
does not affect normal stem cells. This is not the case in all organs,
as c-Myc is not dispensable for homoeostasis in the intestine
(Muncan et al, 2006 no. 114).
Similarly, single rat LA7 cells (six out of nine injections) are able
to initiate the formation of mammary tumours when injected into
the fat pads of immunodeficient mice, suggesting they are
functional cancer stem cells (Zucchi et al, 2007). However, they
also exhibit somatic stem properties in vitro, including both self
renewal and the ability to differentiate into all lineages of the
mammary gland (Zucchi et al, 2007). LA7 cells also express cell
surface markers used to enrich for normal mouse mammary cells
such as CD29 (Shackleton et al, 2006) and CD49f (Stingl et al,
2006). Interestingly, the expression of CD24, which was high in
normal murine mammary stem cells (Shackleton et al, 2006), is
low in LA7 cells (Zucchi et al, 2007) and human mammary cancer
stem cells (Al-Hajj et al, 2003), suggesting a crucial difference
between normal and cancer mammary stem cells which could be
exploited for future therapies.
A definitive comparison between the mammary stem cells used
to derive an entire functional mammary gland (Lin
  CD29
hi
CD24
þ) (Shackleton et al, 2006) and mammary cancer stem cells
(Zucchi et al, 2007) cannot be confidently made as yet, as only
approximately 10% of the single cells implanted were able to
develop into a functional mammary gland. Thus, we cannot say
with any certainty whether the cancer stem cell and somatic stem
cell are exactly the same as certain essential properties are
unknown.
The recently identified intestinal stem cell marker Lgr5 is also
expressed in hair follicle stem cells, as well as tumour tissue from
the colon, liver and ovaries (Barker et al, 2007). Very recent
unpublished data from Hans Clevers’ lab has shown that Lgr5
þ
cells isolated from the bulge region of the hair follicle have the
capacity to form a new hair follicle in vivo (Jaks et al, 2007). This
type of in vivo assay is difficult to perform in the intestine, but
suggests that Lgr5
þ could be a genuine marker of stem cells in
several tissues. Importantly, Lgr5
þ cells in the bulge region are
cycling, and do not overlap with long-term label-retaining cells
which are thought to mark stem cells of many tissues including the
intestine where Lgr5 was first identified. These data further
question the validity of using long-term label-retention as a
surrogate marker of stem cells in adult tissues.
There is growing evidence demonstrating the similarities
between cancer stem cells and normal stem cells, however, this
does not prove that cancer stem cells originate from transformed
normal somatic stem cells located in the same tissue. This raises
the important issue of stem cell plasticity within tissues, with the
Table 1 Functionally defined proposed stem cell and cancer stem cell markers from animal models
Organ
NOD/SCID
assay Stem cell assay Stem cell marker
Cancer stem
cell assay Cancer stem cell marker
Intestine No Lineage tracing and
position in vivo
Lgr5 (Barker et al, 2007) Bmi-1
(Sangiorgi and Capecchi, 2008)
Transplant of cancer
initiating cells in vivo
CD133
+ (O’Brien et al, 2007)
Lung No In vitro stem cell
characteristics
Co-expression of SP-C and CCA
(Sca1
+ CD45
  Pecam
  CD34
+)
(Kim et al, 2005)
Expression in vivo and
response to K-ras
Co-expression of SP-C and
CCA (Sca1
+ CD45
 
Pecam
  CD34
+)
(Kim et al, 2005)
Prostate No In vivo and in vitro
stem-like properties.
CD45
  CD31
 
Ter119
  Sca-1
+ CD49f
+
(Lawson et al, 2007)
Expression in vivo and
response to AKT
Sca1 (Xin et al, 2005)
Skin Yes Entire organ generation
in vivo from a single cell
CD34
+ and a ´6 integrin
(Blanpain et al, 2004)
Transplant of cancer initiating
cells in vivo
CD34
+ (Malanchi, 2008 no. 163)
Mammary Yes Entire organ generation
in vivo from a single cell
Lin
  CD29
hi CD24
+
(Shackleton et al, 2006)
Transplantation of single
cancer initiating cell in vivo
Rat LA7 Cells
(CD24
  CD29
hi CD49f
hi)
(Zucchi et al, 2007)
Normal stem cells in cancer prone epithelial tissues
TJ Phesse and AR Clarke
225
British Journal of Cancer (2009) 100(2), 221–227 & 2009 Cancer Research UKpossibility that both normal and cancer ‘stemness’ can be acquired
from a differentiated phenotype. For normal stem cells, this is
readily demonstrated in the mouse intestine by the recruitment
of a novel population of stem cells following DNA damage.
For cancer cells, nuclear transplantation has been used to clearly
show that reprogramming within an oocyte can re-establish almost
full developmental pluripotency (Hochedlinger et al, 2004).
Notably, these latter experiments were not performed with cells
enriched for a cancer ‘stem cell’ phenotype, suggesting that the
capacity for pluripotency may be retained at a relatively high level
within tumours. Recently, a mechanism for such reprogramming
has been at least partially characterised, as mouse embryonic
fibroblasts have been reprogrammed into ES-like cells through a
co-ordinated expression of Oct4, c-Myc, Klf4 and Sox2 (Wernig
et al, 2007).
Ultimately, there is a need to directly address the relevance of
normal cancer cells to cancer initiating cells and cancer sustaining
cells. Two experiments have recently begun to address this in the
intestine using the normal stem cell markers bmi-1 and Lgr5. Both
Sangiorgi et al (2008) and Barker et al (2008) have used these
markers to drive expression of Cre recombinase within the
intestinal stem cell and thereby deregulate the Wnt pathway,
either by activation of beta-catenin or inactivation of Apc. Both
groups show that intestinal stem cell-specific activation of Wnt
leads to very efficient adenoma formation. Furthermore, Barker
et al (2008) specifically compare this rate of adenoma formation to
that following deletion of Apc in transit-amplifying cells, the latter
being greatly reduced. These experiments therefore strongly
suggest the normal stem cell as the cell of origin for neoplasia,
and that transformation of the intestinal stem cell is a primary
route to intestinal neoplasia. These data also support the cancer
stem cell concept in which a stem cell/progenitor cell hierarchy is
maintained in early adenomas.
SUMMARY
Somatic stem cells are now being identified with increasing
confidence across a range of tumour prone tissues. For many of
these same tissues, cancer stem cells have been identified with
varying degrees of confidence. Although ultimate proof of the
cancer stem cell is lacking for most of these tissues, the
characteristics of these putative populations share at least some
characteristics with normal stem cells. This suggests either that
cancer stem cells directly originate from transformed somatic stem
cells, or that there is a measure of convergent ‘evolution’ of the two
stem cell types. Given the high turnover nature of many of these
tissues, it is tempting to speculate that high activity within the stem
cell compartment directly translates into an increased suscept-
ibility to transformation. However, as yet there is little direct
evidence to confirm or refute this.
The parallels existing between the two cell types do have
implications for tumour therapy. Existing strategies have been
developed to target the majority of cells within the tumour, as they
are often identified through their ability to shrink tumour mass.
However, this may only serve to de-bulk the tumour, potentially
leaving cancer stem cells undamaged and so allow relapse of the
tumour. This problem can potentially be solved by developing
strategies that specifically target the cancer stem cell population.
However, given the overlaps discussed in this review, it will be
critical that these therapies do not also catastrophically impair the
normal somatic stem population.
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